Release
2022/06/23
Osaka, Japan, June 23, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces information relating to the implementation of the acquisition of treasury stock and the cancellation of treasury stock, which were resolved at the Board of Directors meeting held on May 11, 2022. The acquisition and cancellation of the treasury stock was subject to the approval of shareholders at the General Meeting of Shareholders regarding the disposition of treasury stock by way of third-party allotment for the purpose of supporting the activities of the Shionogi Infectious Diseases Research Promotion Foundation, a General Incorporated Foundation. This time, this proposal was approved at the Ordinary General Meeting of shareholders held on June 23, 2022. Details regarding the acquisition and cancellation of treasury stock are as below.
1. Reasons for the acquisition of treasury stock
The acquisition will be made to strengthen shareholder returns and to lead to further improvement of corporate value, as well as to improve capital efficiency and implement an agile capital policy in view of the business environment. In addition, it aims to address the dilution of stock value due to the disposal of treasury stock by way of third-party allotment for the purpose of supporting the activities of the Shionogi Infectious Disease Research Promotion Foundation, a General Incorporated Foundation
2. Details of matters relating to the acquisition of treasury stock
1) Type of stock to be acquired: Common stock of the Company
2) Total number of shares to be acquired: 7,200,000 shares (maximum)
(Represents 2.39% of the total number of shares issued (excluding treasury stock))
3) Total purchase price for acquisition of shares: 50 billion yen (maximum)
4) Period of acquisition: From June 24, 2022 to December 30, 2022 (scheduled)
5) Method of acquisition: Market purchase on the Tokyo Stock Exchange
3. Details of matters relating to the cancellation of treasury stock
1) Type of stock to be cancelled: Common stock of the Company
2) Number of shares to be cancelled: 4,200,000 shares
3) Scheduled date of cancellation: February 10, 2023 (scheduled)
(Reference) Number of treasury shares as of March 31, 2022
Total number of shares issued (excluding treasury stock): 301,482,780 shares
Number of treasury shares: 10,103,385 shares
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html